Billiontoone (BLLN) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is BLLN's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

BillionToOne raised 2026 revenue guidance to $460 million to $470 million. Third-quarter revenue reached $123 million, up 47% year over year.…

BillionToOne, Inc. ( BLLN ) 2026 UBS Global Healthcare Conference November 10, 2026 2:00 PM EST Company Participants Oguzhan Atay - Co-Founder, Chairman & CEO Presentation Unknown Analyst Good afternoon. I'm Doug Schenke…

Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) CTO David Tsao sold 20,000 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $109.24, for a total value of $2…

BillionToOne, Inc. (BLLN) Q3 2026 Earnings Call Transcript…

While the top- and bottom-line numbers for BillionToOne (BLLN) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Stre…

BillionToOne (BLLN) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.1 per share a year ago.…

Billiontoone NASDAQ: BLLN raised its full-year revenue outlook after third-quarter sales rose 47% from a year earlier, driven by growth in both prenatal and oncology testing. The molecular diagnostics company also report…

MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, to…

BillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B market cap. BLLN's Unity Complete offers unmatched prenatal screening convenience and accuracy,…

BillionToOne (BLLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, to…

Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) CEO Oguzhan Atay sold 5,150 shares of the business's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $100.23, for a tot…

MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, to…

BillionToOne a molecular diagnostic company from California, has experienced quite a topsy-turvey journey since its debut in November last year. BLLN is set to hold on to a consistently high GMS of 70%, which reflects th…

Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response Head-to-head comparison shows 94% concordance with tum…

Shares of Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) were down 4.6% on Wednesday after an insider sold shares in the company. The stock traded as low as $112.75 and last traded at $112.72. 74,648 shares changed …

The Centers for Medicare & Medicaid Services plans to align its 2027 clinical laboratory fee schedule rates with private sector payer rates, aiming to curb excessive Medicare payments and save taxpayers an estimated $1 b…

The transaction involved 1,416 shares at a weighted average price of $97.54 per share, totaling $138,116 on Sept. 9, 2026. The sale involved shares equal to 5% of the direct equity position held before the transaction.…

The transaction involved 30,331 shares executed at a weighted average price of $99.91 per share on September 14, 2026. The shares traded in this filing represented 100% of the insider's directly-held equity stake, and a …

MENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today …

New add-on test from a single blood draw; BillionToOne also expands Northstar Select® panel to 102 genes MENLO PARK, Calif., Sept. 1, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular di…

The transaction involved 10,000 shares at a weighted-average price of $100.00 per share, totaling $1.0 million on the August 25, 2026 transaction date. Following the disposal, the insider holds a direct position of 1,000…

/C O R R E C T I O N -- BillionToOne/ PR Newswire MENLO PARK, Calif., Aug. 18, 2026 I…

Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA results MENLO PARK, Calif., Au…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

